Nanomedicine-based immunotherapy – Concepts, entrepreneurship & clinical translation

Our body harnesses lipoproteins as dynamic nanodelivery systems to efficiently transport fats and macromolecules between different organs and cells. These dynamic assemblies of apolipoproteins and lipids, recreated in the lab through advanced recombinant technologies and microfluidics, enable innovative nanomedicine and controlled release systems.

Mulder’s research explores how apolipoproteins serve as robust scaffolds for designing nanomedicines with superior safety profiles and intrinsic immune cell targeting capabilities. Backed by nearly two decades of bioengineering advancements, this approach drives academic research, fosters a breeding ground for bioengineering talent and fuels biotech startups, accelerating the translation of these concepts into clinical applications to benefit patients.

BIO
Willem Mulder is a biomedical engineer, an academic and entrepreneur. He develops innovative, bioengineered nanomedicines and controlled release systems for immunotherapy in cancer, inflammatory and cardiovascular diseases, and to prevent allograft rejection in organ transplantation. 

After acquiring a Ph.D. in biomedical engineering from the Eindhoven University of Technology in 2006, Mulder was recruited to the Icahn School of Medicine at Mount Sinai in New York. He founded Mount Sinai’s Nanomedicine Lab and became tenured Professor of Radiology and Professor of Oncological Sciences. Mulder has published more than 200 papers in top scientific journals, such as Cell, Nature Nanotechnology, Nature Biomedical Engineering, Immunity, Science Translational Medicine.